Next Article in Journal
Genetics of Functional Seizures; A Scoping Systematic Review
Previous Article in Journal
Mitochondrial DNA in Human Diversity and Health: From the Golden Age to the Omics Era
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Genes
Volume 14
Issue 8
10.3390/genes14081536
genes-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era

by
Manuela Schubert Baldo
1,
Célia Nogueira
1,2,
Cristina Pereira
1,2,
Patrícia Janeiro
3,
Sara Ferreira
4,
Charles M. Lourenço
5,
Anabela Bandeira
6,
Esmeralda Martins
6,7,
Marina Magalhães
8,
Esmeralda Rodrigues
9,
Helena Santos
10,
Ana Cristina Ferreira
11 and
Laura Vilarinho
1,2,*
1
Research and Development Unit, Human Genetics Department, National Institute of Health Doutor Ricardo Jorge, 4000-055 Porto, Portugal
2
Neonatal Screening, Metabolism and Genetics Unit, Human Genetics Department, National Institute of Health Doutor Ricardo Jorge, 4000-055 Porto, Portugal
3
Inherited Metabolic Disease Reference Center, Lisbon North University Hospital Center (CHULN), EPE, 1649-028 Lisbon, Portugal
4
Inherited Metabolic Disease Reference Center, Pediatric Hospital, Hospital and University Center of Coimbra, 3004-561 Coimbra, Portugal
5
Neurogenetics Department, Faculdade de Medicina de São Jose do Rio Preto, São Jose do Rio Preto 15090-000, Brazil
6
Oporto Hospital Centre, University of Porto, 4099-001 Porto, Portugal
7
Unit for Multidisciplinary Research in Biomedicine, Instituto de Ciências Biomédicas Abel Salazar, Porto University, 4050-313 Porto, Portugal
8
Department of Neurology Porto Hospital and University Centre, EPE, 4050-011 Porto, Portugal
9
Reference Center for Inherited Metabolic Disorders, University Hospital Centre S. João, 4200-319 Porto, Portugal
10
Department of Pediatrics, Hospital Centre, EPE, 4434-502 Vila Nova de Gaia, Portugal
11
Department of Pediatrics, Hospital D. Estefânia, 1169-045 Lisbon, Portugal
 
add Show full affiliation list
 
remove Hide full affiliation list
*
Author to whom correspondence should be addressed.
Genes 2023, 14(8), 1536; https://doi.org/10.3390/genes14081536
Submission received: 26 June 2023 / Revised: 21 July 2023 / Accepted: 24 July 2023 / Published: 27 July 2023
(This article belongs to the Section Genetic Diagnosis)
Browse Figure
Review Reports Versions Notes

Abstract

:
Mitochondrial diseases are the most common inherited inborn error of metabolism resulting in deficient ATP generation, due to failure in homeostasis and proper bioenergetics. The most frequent mitochondrial disease manifestation in children is Leigh syndrome (LS), encompassing clinical, neuroradiological, biochemical, and molecular features. It typically affects infants but occurs anytime in life. Considering recent updates, LS clinical presentation has been stretched, and is now named LS spectrum (LSS), including classical LS and Leigh-like presentations. Apart from clinical diagnosis challenges, the molecular characterization also progressed from Sanger techniques to NGS (next-generation sequencing), encompassing analysis of nuclear (nDNA) and mitochondrial DNA (mtDNA). This upgrade resumed steps and favored diagnosis. Hereby, our paper presents molecular and clinical data on a Portuguese cohort of 40 positive cases of LSS. A total of 28 patients presented mutation in mtDNA and 12 in nDNA, with novel mutations identified in a heterogeneous group of genes. The present results contribute to the better knowledge of the molecular basis of LS and expand the clinical spectrum associated with this syndrome.

1. Introduction

Mitochondrial disorders (MD) are the most common group of inherited metabolic disorders. These disorders might result from mutations in mtDNA, nDNA, or even genome interplay misfunctioning. In pediatric populations, LS is the most frequent neurodegenerative MD, reaching up to 1:40.000 live births [1,2]. It encloses progressively fatal neurologic failure, high lactate levels, and characteristic symmetrical lesions in brain stem and basal ganglia [2,3]. The diagnostic criteria include clinical, neuroradiological, biochemical, and molecular findings. The developments in molecular diagnosis enabled an easy recognizing of this pathology but also expanded the phenotypical features, as well as the knowledge on the molecular basis of this syndrome. Since Holt et al. first reported m.8993T>G in 1990 [4], several mutations in MT-ATP6 were subsequently published, also associated with LS, such as 9176T>C [5] and m.10191T>C [6]. The quick advance in nDNA sequencing provided helpful information since biochemical studies and mtDNA sequencing do not allow diagnosis confirmation in every cases. Fatal early-onset presentations, classically seen associated with complex I (CI) deficiency [7,8], were importantly explored through sequencing of structural mitochondrial respiratory chain (MRC) components coding genes. Additional clinical presentations that did not fulfill the clinical and/or radiological criteria for LS but strongly resembled the syndrome were named Leigh-like syndrome (LLS), considering that the evolution of symptoms could be sufficient to complete LS criteria in the future [1,2,9]. Since LLS is diagnosed in patients with nuclear-gene-related mutations, the condition is now denominated Leigh syndrome spectrum (LSS) [9], where LS and LLS are considered a probable continuum of the same disorder [9,10] (Table 1). The molecular advances through NGS and genomics made it possible to obtain huge amounts of information in a timely way, enabling an increase in diagnosis sensitivity, but bringing some uncertainties [11]. The plethora of information produced by these technologies demanded new data for comparison that is not widely available or extensively established. Furthermore, these techniques demand time and expertise to build robustness [12,13]. In mtDNA, for example, identifying a pathogenic variant may allow a condition to be named, but might fail to explain different phenotypes associated with a common underlying genetic lesion and intrafamilial phenotypic differences [14]. To address these questions, precision medicine was evolved through approaches known by “omics” (metabolomics, proteomics, and transcriptomics). The integrative medicine studies dive into deep microenvironments to solve these questions. Despite recent advances it is still too early to apply it in routine testing [15]. While precision medicine is not routine, molecular biology refinements are eventful in promoting faster diagnosis and supporting interventions and counseling to LSS patients.
Unfortunately, there are no curative options for MD yet. Supporting treatment is still the best and only option, and includes dietary management, cofactors administration, specific support of disabilities, and respiratory intervention. Clinical trials for treatments, such as mTOR inhibitors, EPI-743, are undergoing to evaluate its effectiveness in preventing mortality and morbidity, with promising results [16]. In this paper we present data from a cohort of 40 patients diagnosed with LSS highlighting the genetic heterogeneity identified in our cohort, contributing to expand the LSS.

2. Materials and Methods

Patients:
A cohort of 40 confirmed LSS individuals, from birth (0 months old (m.o.)) to 36 years, 20 males and 20 females, and respective positive family members, were followed in different clinical reference centers from Portugal. From this group, 11 had already been reported by our group and the remaining 29 were molecularly characterized and reported here for the first time. This study was approved by the Ethics Committees of the National Institute of Health Doutor Ricardo Jorge, and informed consent for genetic studies was obtained from all investigated subjects, or their relatives, in agreement with the Declaration of Helsinki.
DNA extraction, sequencing, and variant analysis:
High-purity DNA was extracted from peripheral blood leucocytes and/or muscle biopsy material according to standard procedures. A custom-made targeted nuclear gene panel was designed using Suredesign software (Agilent 2023 7.10.1.1, Agilent Technologies, Santa Clara, CA, USA) and includes 209 nuclear genes, from which 188 were known to be involved in MD and 21 were candidates based on their role or participation in different pathways that include genes responsible for clinical presentations mimicking MD (Appendix A). Genes of interest were captured with a SureSelect QXT kit (Agilent Technologies), followed by sequencing on the Illumina MiSeq platform. Variant calling and annotation were performed using available commercial programs such as Surecall (Agilent Technologies) and wAnnovar (wannovar.wglab.org/ (accessed on 23 January 2023)). Variants were filtered, taking into account (i) the type of pathogenic variant (missense, frameshift, stop-gain or stop-loss, and splice-site variants), (ii) in silico predictors (SIFT, PolyPhen-2, MutationTaster) [17,18,19] and presence in databases (dbSNP, 1000 Genomes, HGMD professional, ClinVar, ExAC, OMIM, gnomAD), and (iii) the population frequency (variants with a minor allele frequency (MAF) > 1% in the 1000 Genomes Project (http://www.1000genomes.org (accessed on 23 January 2023) and Exome Variant Server databases (http://evs.gs.washington.edu (accessed on 23 January 2023) were filtered out). Furthermore, we searched copy number variations through the analysis of coverage data, using cnMOPS [20]. The entire human mtDNA was enriched by a single amplicon, using back-to-back primers, by long-range PCR [21]. Indexed paired-end DNA libraries were prepared and an equimolar pool was sequenced, according to the manufacturer’s instructions. FASTQ files were aligned to the mtDNA reference sequence with SeqMan NGen (DNAStar). Variant calling and annotation were performed using the following commercial programs: SeqMan NGen and SeqMan Pro (DNASTAR). Variants were filtered considering (i) the type of pathogenic variant, (ii) the population frequency, (iii) in silico predictors and presence in databases (Mitomap, MitImpact2, HmtVar), and (iv) heteroplasmy > 5%. All variants detected that had the potential to be disease-causing were confirmed by Sanger sequencing using the BigDye Terminator Cycle Sequencing Version 3.1 (Applied Biosystems, Foster City, CA, USA), and analyzed on an ABI 3130XL DNA Analyzer. When DNA from additional family members was available, co-segregation studies were also performed [22].

3. Results

3.1. Mitochondrial DNA Mutations

A total of 28 out of 40 patients, 14 males and 14 female patients, presented mutations in mtDNA. The MT-ATP6 gene was the most frequent spot of mutations identified in our cohort, corresponding to 48% of the patients. The previously known m.8993T>G (p.Leu156Arg) and m.8993T>C (p.Leu156Pro) are present in 16 patients: 12 patients T>G and four patients T>C (P1 to P16). P7’s mother presented the same mutation m.8993T>G and same heteroplasmy of her child, but exhibiting the neuropathy, ataxia, and retinitis pigmentosa (NARP) phenotype. Two other mutations were identified in the MT-ATP6 gene: m.9185T>C (p.Leu220Pro) in two patients (P17 and P18) and the m.9176T>G (p.Leu217Arg) in P19, who had low citrulline levels identified on neonatal screening and confirmed on plasma amino acid analysis by ion exchange chromatography. Other, less frequent mutations were identified in our cohort in other mtDNA genes associated with LSS were m.6547T>C (p.Leu215Pro), m.4142G>T (p.Arg279Leu), m.3243A>G, m.10197G>A (p.Ala47Tre), m.10191T>C (p.Ser45Pro), m.13094T>C (p.Val253Ala), m.13513G>A (p.Asp393Asn), and a single-large-scale deletion of 4977bp (Table 2). In MT-TL1, the m.3243A>G mutation was identified in P20. The family, namely, mother and two siblings, underwent investigation and all of them harbored the m.3243A>G mutation, but no symptoms were reported at the time. Two other patients had mutations in MT-ND3: P21 had m.10191T>C (p.Ser45Pro) mutation, and in P22 we found m.10197G>A (p.Ala47Pro) in nearly homoplasmic state. In MT-ND5 we identified mutations in three patients: P23 was positive for m.13094T>C (p.Val253Ala), and P24 and P25 with m.13513G>A (p.Asp393Asn). In MT-ND1, we identified the mutation m.4142G>T (p.Arg279Leu) in P26 and MT-CO1 P27 was found to have m.6547T>C (p.Leu215Pro). P28 was diagnosed in the first decade of life through a Southern-blot analysis attesting a single-large-scale deletion of 4977 bp (m.8470-m.13447) in 61% of heteroplasmy in muscle, the most common deletion in the mtDNA (Table 2).

3.2. Nuclear DNA Mutations

A targeted 209 nuclear-gene panel allowed molecular characterization of 12 of the 40 patients, five males and seven females, which presented mutations in SLC19A3, NDUFV2, NDUFS8, NDUFS1, POLG, SURF1, LRPPRC, and HIBCH (Table 3). In nuclear genes associated with CI, we found mutations in four patients: P29 presented in compound heterozygosity in NDUFS8, the previously reported mutations c.196C>T (p.Arg66*) and c.287G>A (p.Arg96His); in P30 we identified a compound heterozygous for NDUFS1c.470A>T (p.Lys157Met) and c.1798G>C (p.Glu600Gln), which are not reported in databases. Segregations studies confirmed inheritance, and these variants are class IV according to the American College of Medical Genetics (ACMG) scoring system classification [32]. P31 was homozygous for NDUFV2 splicing mutation c.120+5_120+8delGT, previously described in the literature, which was also identified by prenatal test in her sibling (P32) [22]. In nuclear genes of CIV, we identified mutations in four patients: P33, P34, P35, and P36. P33 and P34 are siblings with different clinical symptoms, and the investigation by NGS retrieved c.19_35dup17* (p.Ala13Cysfs*65)/c.845_846del (p.Ser282Cysfs*9) mutations in SURF1, while P35 had isolated psychiatric symptoms and also presented the mutation c.19_35dup17* (p.Ala13Cysfs*65), in homozygous condition, in SURF1. P36 was also studied by NGS and was revealed to be homozygous c.74G>A (p.Arg25His) in LRPPRC, previously unreported in the literature, which is a class III according to ACMG scoring system classification [32]. Despite fitting into the phenotype and confirmative segregations studies, it remains as VUS, as we will discuss. Co-factors such as thiamine are also related to LSS. We had two patients investigated in our cohort manifesting symptoms of biotin-responsive basal ganglia disease (BBGD), P37, and P38, which presented homozygous mutations c.74dupT (p.Ser26Leufs*19) and c.980-14A>G, respectively, in SLC19A3 [33]. The patients P39 and P40 had abnormal metabolic work-up with increased dried blood spot propionylcarnitine (C3) in the acylcarnitine profile (by tandem mass spectrometry MS/MS) and increased erytro-2-methyl-2,3-dihydroxybutyric acid and 3-methyl-glutaconic acid in urinary organic acids profile by gas chromatography/mass spectrometry (GC/MS). The NGS gene panel identified in P39 homozygous mutation c.488G>T (p.Cys 163Phe) and in P40 c.129dupA (p.Gly44Argfs*20)/c.910C>T (p.Pro304Ser) in HIBCH, coherent to an organic aciduria due to a disturbance in valine catabolic pathway to be further discussed [34,35]. All identified nuclear mutations in this cohort are shown in Figure 1.

4. Discussion

The first group of patients in our cohort were molecularly characterized using targeted molecular approaches, the only available in previous decades, as PCR/RFLP and sanger sequencing of selected gene regions. The complete mtDNA sequencing by NGS was an important achievement that enabled the analysis of the total mtDNA genes, increasing the detection power and allowing the identification of several other mutations already linked to other phenotypes that are now part of the LSS. A total of 48% of the patients from our cohort presented mutations in the MT-ATP6 gene, which is higher than could be expected based on published results [39]. This result could be the reflection of a particular molecular background of Portuguese LSS patients, or a bias associated with the studied cohort. Most index cases had m.8993T>G/C with mutation loads over 95% in muscle and/or blood and recurrent symptoms such as hypotonia, weakness, neurodevelopmental delay or regression, epilepsy, movement disorders, and deafness. The discovery of variable phenotypes of m.8993T>G/C was important to distinguish LSS from and NARP [40], for which the heteroplasmic rates showed that LSS classically display higher than 85% and NARP up to 85%. An additional explanation for the differences in clinical expression is the highly conserved position in MT-ATP6 resulting in less tolerance to T>G rather than T>C in 8993-point mutations due to the amino acid change, as T>C results in maintaining nonpolar amino acids while the T > G results in substitution of nonpolar amino acid for a charged one, which could produce an important destabilization in the catalytic site of the ATP synthase where this mutation occurs [4,16,41]. In family members of our cohort, we identified two mothers with 75% of heteroplasmy in m.8993T>G: one yet asymptomatic, the other exhibiting NARP syndrome. P7′s mother with NARP displayed the same heteroplasmic rates, but this was calculated in DNA extracted from blood, while P7′s heteroplasmy was accessed in muscle tissue, making the correlation difficult to perform. Our hypothesis for the observed clinical presentations is based not only on the overall different mutation load but also on the distribution of mutated mtDNA by the different tissues. Plasma amino acids profiles can exhibit changes that point to these mutations, namely, low citrulline levels [42,43]. Even at newborn screening (and after excluding urea cycle disorders), low citrulline is suggestive of MT-ATP6 mutations 8993T>G/C and m.9176T>C/G [44]. A recent paper [45] tried to correlate these mutations to an assertive metabolic profile phenotype, such as the one we found in P19, with low citrulline levels at newborn screening and m.9176T>G (p.Leu217Arg) in homoplasmy [45]. The study’s results showed that reduced citrulline levels and increased propionylcarnitine (C3) and 3-hydroxy-isovaleryl/2-methyl-butyrylcarnitine (C5-OH) might be associated with MT-ATP6 mutations [45,46]. P17 was investigated due to psychomotor delay, hypotonia, and microcephaly and harbors m.9185T>C (p.Leu220Pro) in 70% of mtDNA molecules while P18 had an LSS and harbors the same mutation in homoplasmy. This mutation is particularly relevant in LSS presenting with ataxia and late-onset cases where ataxia is the core symptom [47,48], albeit fulminant presentation being known as an early-onset LSS with infantile spasms with this mutation [49].
In the tRNAleu MT-TL1, the MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes) mutation m.3243A>G has been also identified in different phenotypes such as LSS, maternally inherited deafness and diabetes (MIDD), and isolated myopathy [50,51,52]. In our cohort, P20 presented m.3243A>G and epilepsy, ataxia, hyperlactacidemia, and learning disabilities, with imaging studies characteristics of LSS, an expected phenotype to this mutation [31]. The m.3243A>G usually has a variable heteroplasmy percentage in different tissues and does not respect the usual threshold for MD, as mentioned by Chinnery et al. and by Pann et al. [50,53]. Another mutated gene associated with LSS is MT-ND3, where we also found mutations in our cohort. The m.10191T>C (p.Ser45Pro) may manifest as a remarkable CI deficiency, inducing an early neonatal fulminant phenotype [54] or milder cases of encephalopathy, such as P21 [55], and small fiber neuropathy [56], but configuring dystonia and dysarthria as main symptoms [57]. It can also be associated with a slowly clinical progression from infancy to adulthood [58], leading to the association of mtDNA mutations to “spectrum” nomenclature, which was only acknowledged to nDNA mutations [9]. P22 with the mutation m.10197G>A (p.Ala47Thr) in MT-ND3 also presented a mild phenotype, similar to P21. Mutations in the MT-ND5 gene were also identified in our cohort. We found m.13094T>C (p.Val253Ala) in homoplasmy in P23, a mutation previously described associated with cerebellar syndromes [59], CI deficiency, or combined complexes deficiencies [60], presenting our patient a marked hypotonia. In pediatric populations, LSS appears to represent a less favorable prognosis [61]. P24 and P25 presented m.13513G>A (p.Asp393Asn), a mutation that has already been outlined by Ruiter et al. in a patient with CI deficiency, cardiac rhythm perturbation, and optic atrophy [62], with our patients presenting cardiomyopathy and hypotonia, and ataxia and apnea, respectively. Our cohort also includes a patient with m.4142G>T (p.Arg279Leu) in MT-ND1 (P26 [30]) and another one with m.6547T>C in MT-CO1 (P27 [30]).
Another group of mutations in mtDNA are the rearrangements, such as single-large-scale mtDNA deletions (LMD), a genetic cause of MD expressing a wide range of clinical features. The rearrangements result into a spectrum of syndromes: Pearson, Kearns Sayre Syndrome (KSS), a subtype of chronic progressive external ophthalmoplegia (CPEO), and CPEO itself [63,64]. P28 was investigated due to epilepsy, short stature, cerebellar ataxia, and tremor, and Southern-blot analysis detected an LMD of 4977bp-del (m.8470-m.13447). This association is extremely rare because the early-onset spectrum of LMD, Pearson syndrome, is usually a potentially fatal disorder disabling the progression of the spectrum to other clinical entities, namely, LSS, which makes the association rare [65,66]. Despite the prognosis, the patients who survive may develop LSS or a multiorgan deficiency in the future [63].
The patients of our cohort identified with nDNA mutations were all screened by NGS, which represents a satisfactory middle-term cost-utility approach, providing a significant amount of data in a reasonable time, delivering a broader diagnostic performance when set side by side to conventional procedures. The complexes are the major structural components of the MRC resulting in mitochondrial optimized ATP generation [57]. As we observed in our cohort, the CI and CIV most frequently harbor pathogenic mutations, followed by non-OXPHOS defects. In total, in nDNA we identified ten pathogenic mutations, three likely-pathogenic variants, one reclassified in our perspective through ACMG, symptomatology, and biochemical analysis, and one VUS that did not meet criteria to be reclassified.
The CI is the first and largest MRC complex [67] and is widely associated with LSS, with several genes involved [3,57], resulting in 33 subtypes of mitochondrial CI deficiency (MCID), from first year of life rapidly progressing to fatal course [68,69] to a wide range of presentations [70,71,72]. P30 presented the c.470A>T (p.Lys157Met)/c.1798G>C (p.Glu600Gln) variants in NDUFS1, which are not reported in databases so far. Standard classification scores by ACMG resulted in class IV, likely pathogenic, for both variants. In silico predictors such as Polyphen-2 and SIFT described them as deleterious, and Mutation Taster as probably damaging. Segregation studies showed heterozygous parents. The clinical manifestations are described in LSS and CI deficiency, altogether supporting a probable pathogenicity. P31 displayed, with homozygous mutation, c.120+5_120+8delGT in NDUFV2, a classic NDUFV2 phenotype represented by hypertrophic cardiomyopathy and encephalopathy [73,74], alongside with a rare skin condition. In less frequent cases, NDUFV2 mutations manifest as LSS, which was reported by Liu et al. in two families [75].
The CIV Is also a critical part of the MRC as the terminal catalytic site to transfer electrons into oxygen [76]. SURF1 is a gene that plays part in the assembly of CIV, while LRPPRC impacts the mitochondrial translation [77]. We identified P35 with SURF1 mutations displaying atypical presentation with isolated psychiatric symptoms represented by visual hallucinations with suggestive LSS neuroimaging. Molecular assessment retrieved homozygous c.19_35dup17* (p.Ala13Cysfs*65) in SURF1, a gene typically related to a group of homogeneous symptoms (hypertrichosis [78] and peripheral neuropathy), specific imaging findings (leukodystrophy), and high mortality in childhood [79]. However, heterogeneous phenotypes linked to SURF1 mutations have been reported [80]. P36 was investigated for encephalopathy and brain atrophy. NGS revealed the homozygous mutation c.74G>A (p.Arg25His) in LRPPRC gene, a rare variant in population, classified as ACMG class III. Segregation studies were performed, confirming inheritance in our patient. In silico predictors are controverse; Polyphen-2 and SIFT pointing to deleterious role, and Mutation Taster to benign role, while ClinVar classifies it as a VUS associated with congenital lactic acidosis Saguenay-Lac-Saint-Jean, a subtype of LSS [81]. This feature gives us a likely connection between the genotype and the patient’s phenotype, with this variant having the potential to be, in the future, reclassified as likely pathogenic.
Thiamine pyrophosphate is an important cofactor of several steps in energy production and SLC19A3, a biotin-dependent thiamine transporter in the central nervous system, is fundamentally present in the basal ganglia system [82]. BBGD is a well-known cause of LSS [83] frequently manifesting in childhood with vomiting, seizures, encephalopathy, movement disorders, and free-thiamine dosage in cerebrospinal fluid typically low to absent [84,85]. P37 and P38 investigated in our cohort had mutations in SLC19A3. P37 developed neonatal epileptic encephalopathy with homozygous c.980-14A>G in SLC19A3 and P38 displayed episodic ataxia with homozygous c.74dupT (p.Ser26Leufs*19). Both patients are under treatment with biotin and thiamine and had important recovery of symptoms, which demonstrates the importance of recognizing the phenotype and starting effective intervention [82,83].
Organic acidurias are also a proven cause of LSS. In the case of ECHS1 and HIBCH genes, encoding a hydratase and a hydrolase enzyme, respectively, in the final valine metabolism, LSS is the most common clinical manifestation of these genetic deficiencies [86,87,88]. Frequent symptoms identified in these cases are developmental delay or regression, hypotonia, and epilepsy [89]. A recent Spanish study demonstrated that HIBCH deficiency was completely correlated to LSS, and ECHS1 deficiency displayed LSS, but also fatal neonatal lactic acidosis and paroxysmal dystonia. The biochemical profile was divergent between them, which could guide the diagnosis [90]. P39 was confirmed with HIBCH deficiency, being homozygous for c.488G>T (p.Cys 163Phe). P40 is a compound heterozygous for a known pathogenic mutation in HIBCH c.129dupA (p.Gly44Argfs*20) alongside an unreported variant c.910C>T (p.Pro304Ser). The new variant meets ACMG criteria as class III. In silico estimates in Polyphen-2, SIFT, Mutation Taster suggest a deleterious behavior. Also, in this case, the positive segregation pattern, clinical manifestations expressed as LSS and biochemical analysis of acylcarnitine profile displaying elevation of 3-hydroxyisobutyryl carnitine, and urinary organic acids showing intermediate metabolites of valine degradation were associated with a reported pathogenic variant we would consider to be a likely pathogenic variant, ACMG Class IV, under this information.

5. Conclusions

The present work presents data on a Portuguese cohort of 40 LS patients and allows the expansion of the molecular knowledge on this syndrome and the clinical spectrum associated with it. The present data stress the high clinical and genetic heterogeneity associated with this syndrome. The evolution of the molecular technics from PCR/RFLP to sanger sequencing and finally NGS was a path leading to an unprecedent increase in sensitivity in the diagnosis of LS. The adoption by our lab of NGS allowed the clarification of unsolved cases for many years, being useful in revealing the molecular etiology in children and adult patients by identifying new variants, characterizing more cases, and expanding the LSS scenery of mutations, since rare and nondescribed variants were pivotal for our cases; albeit this is only the beginning.

Author Contributions

Conceptualization, M.S.B., C.N. and L.V.; methodology, M.S.B., C.N. and C.P.; patient selection and clinical evaluation, P.J., S.F., C.M.L., A.B., E.M., M.M., E.R., H.S. and A.C.F.; molecular data analysis, M.S.B., C.N. and C.P.; writing—original draft preparation, M.S.B., C.N. and C.P.; writing—review and editing, M.S.B., C.N. and C.P.; supervision, L.V. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by FCT (PTDC/DTP-PIC/2220/2014) and NORTE2020 (NORTE-01-0246-FEDER-000014).

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Ethics Committee “Comissão de Ética para a Saúde do INSA, I.P” INSA-IM60_05.

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

Data is contained within the article.

Acknowledgments

We would like to thank the physicians involved in this work contributing to our casuistic: Margarida Coelho, Elisa Leão Teles, Clara Barbot, Sérgio Castedo, Gabriela Soares, Humberto Vassal, Paula Fonseca, Luísa Diogo, José Pedro Vieira, Márcia Martins, Ana Gaspar, Ana Luísa Rodrigues, Tiago Santos, Miguel Milheiro, Francisco Pinho, Rita Jotta, and José Vale.

Conflicts of Interest

The authors declare no conflict of interest.

Appendix A

Nuclear Gene Panel for Mitochondrial Disorders

AARS2; ABCB7; ACAD9; ACO2; ADCK3; AGK; AIFM1; ALAS2; ALG13; APTX;ATP13A2; ATP5A1; ATP5E; ATPAF2; AUH; BCS1L; BOLA3; C10ORF2; C12ORF65; C19ORF12; C9ORF116; CARS2; CHKB; CISD2; CLN3; CLN5; CLN6; CLN8; CLPB; COA3; COA5; COQ2; COQ4; COQ6; COQ9; COX10; COX14; COX15; COX20; COX4I2; COX5A; COX5B; COX6A1; COX6B1; COX7B; CTSD; CTSF; CWF19L1; CYC1; DARS2; DGUOK; DLAT; DLD; DNA2; DNAJC19; DNAJC5; DNM1L; DOLK; EARS2; ECHS1; ELAC2; ETFA; ETFB; ETFDH; ETHE1; FARS2; FASTKD2; FBXL4; FDX1L; FLAD1; FOXRED1; GDAP1; GFER; GFM1; GLRX5; GRN; GTPBP3; HACE1; HARS2; HCCS; HIBCH; IARS2; IBA57; ISCU; KARS; KCTD7; KIF5A; LARS; LARS2; LIAS; LIPT1; LRPPRC; LYRM4; LYRM7; MARS2; MEGF10; MFF; MFN1; MFN2; MFSD8; MGME1; MICU1; MPC1; MPI; MPV17; MRPL23; MRPL3; MRPL44; MRPL50; MRPL57; MRPS16; MRPS22; MTFMT; MTO1; MTPAP; NARS2; NDUFA1; NDUFA10; NDUFA11; NDUFA12; NDUFA2; NDUFA4; NDUFA9; NDUFAF1; NDUFAF2; NDUFAF3; NDUFAF4; NDUFAF5; NDUFAF6; NDUFB3; NDUFB9; NDUFS1; NDUFS2; NDUFS3; NDUFS4; NDUFS6; NDUFS7; NDUFS8; NDUFV1; NDUFV2; NFU1; NOTCH3; NUBPL; OPA1; OPA3; PARS2; PC; PCK2; PDHA1; PDHB; PDHX; PDP1; PDSS1; PDSS2; PLD1; PMM2; PNPT1; POLG; POLG2; PPT1; PPT2; PUS1; RARS2; RMND1; RNASEH1; RRM2B; SARS2; SCO1; SCO2; SDHA; SDHAF1; SDHAF2; SDHB; SDHC; SDHD; SERAC1; SLC19A3; SLC25A22; SLC25A3; SLC25A4; SLC25A42; SLC4A3; SLC52A1; SLC52A2; SLC52A3; SPATA5; SUCLA2; SUCLG1; SURF1; TACO1; TARS2; TAZ; TIMM8A; TK2; TMEM126A; TMEM126B; TMEM70; TPK1; TPP1; TRMU; TRNT1; TSFM; TTC19; TUFM; TYMP; UQCRB; UQCRC2; UQCRQ; VARS2; WARS2; WDR45; WFS1; YARS2.

References

  1. Lake, N.J.; Compton, A.G.; Rahman, S.; Thorburn, D.R. Leigh Syndrome: One Disorder, More than 75 Monogenic Causes: Leigh Syndrome. Ann. Neurol. 2016, 79, 190–203. [Google Scholar] [CrossRef]
  2. Rahman, S.; Blok, R.B.; Dahl, H.-H.M.; Danks, D.M.; Kirby, D.M.; Chow, C.W.; Christodoulou, J.; Thorburn, D.R. Leigh Syndrome: Clinical Features and Biochemical and DNA Abnormalities. Ann. Neurol. 1996, 39, 343–351. [Google Scholar] [CrossRef] [PubMed]
  3. Baertling, F.; Rodenburg, R.J.; Schaper, J.; Smeitink, J.A.; Koopman, W.J.H.; Mayatepek, E.; Morava, E.; Distelmaier, F. A Guide to Diagnosis and Treatment of Leigh Syndrome. J. Neurol. Neurosurg. Psychiatry 2014, 85, 257–265. [Google Scholar] [CrossRef]
  4. Holt, J.; Harding, A.E.; Petty, R.K.H.; Morgan-Hughes, J.A. A New Mitochondrial Disease Associated with Mitochondrial DNA Heteroplasmy. Am. J. Hum. Genet. 1990, 46, 428–433. [Google Scholar]
  5. Carrozzo, R.; Tessa, A.; Vazquez-Memije, M.E.; Piemonte, F.; Patrono, C.; Malandrini, A.; Dionisi-Vici, C.; Vilarinho, L.; Villanova, M.; Schagger, H.; et al. The T9176G MtDNA Mutation Severely Affects ATP Production and Results in Leigh Syndrome. Neurology 2001, 56, 687–690. [Google Scholar] [CrossRef] [PubMed]
  6. Taylor, R.W.; Singh-Kler, R.; Hayes, C.M.; Smith, P.E.M.; Turnbull, D.M. Progressive Mitochondrial Disease Resulting from a Novel Missense Mutation in the Mitochondrial DNA ND3 Gene. Ann. Neurol. 2001, 50, 104–107. [Google Scholar] [CrossRef]
  7. Shoubridge, E.A. Nuclear Genetic Defects of Oxidative Phosphorylation. Hum. Mol. Genet. 2001, 10, 2277–2284. [Google Scholar] [CrossRef] [Green Version]
  8. Janssen, R.J.R.J.; Nijtmans, L.G.; Heuvel, L.P.V.D.; Smeitink, J.A.M. Mitochondrial Complex I: Structure, Function and Pathology. J. Inherit. Metab. Dis. 2006, 29, 499–515. [Google Scholar] [CrossRef]
  9. Rahman, S.; Thorburn, D. Nuclear Gene-Encoded Leigh Syndrome Spectrum Overview; University of Washington: Seattle, WA, USA, 2020. [Google Scholar]
  10. Thorburn, D.R.; Rahman, J.; Rahman, S. Mitochondrial DNA-Associated Leigh Syndrome and NARP. In Mitochondrial DNA; University of Washington: Seattle, WA, USA, 2017. [Google Scholar]
  11. Forny, P.; Footitt, E.; Davison, J.E.; Lam, A.; Woodward, C.E.; Batzios, S.; Bhate, S.; Chakrapani, A.; Cleary, M.; Gissen, P.; et al. Diagnosing Mitochondrial Disorders Remains Challenging in the Omics Era. Neurol. Genet. 2021, 7, e597. [Google Scholar] [CrossRef] [PubMed]
  12. Kremer, L.S.; Wortmann, S.B.; Prokisch, H. “Transcriptomics”: Molecular Diagnosis of Inborn Errors of Metabolism via RNA-Sequencing. J. Inherit. Metab. Dis. 2018, 41, 525–532. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Stenton, S.L.; Kremer, L.S.; Kopajtich, R.; Ludwig, C.; Prokisch, H. The Diagnosis of Inborn Errors of Metabolism by an Integrative “Multi-omics” Approach: A Perspective Encompassing Genomics, Transcriptomics, and Proteomics. J. Inherit. Metab. Dis. 2020, 43, 25–35. [Google Scholar] [CrossRef]
  14. Finsterer, J.; Laccone, F. Phenotypic Heterogeneity in 5 Family Members with the Mitochondrial Variant m.3243A>G. Am. J. Case Rep. 2020, 21, e927938. [Google Scholar] [CrossRef]
  15. Rahman, J.; Rahman, S. Mitochondrial Medicine in the Omics Era. Lancet 2018, 391, 2560–2574. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  16. Bakare, A.B.; Lesnefsky, E.J.; Iyer, S. Leigh Syndrome: A Tale of Two Genomes. Front. Physiol. 2021, 12, 693734. [Google Scholar] [CrossRef] [PubMed]
  17. Kumar, P.; Henikoff, S.; Ng, P.C. Predicting the Effects of Coding Non-Synonymous Variants on Protein Function Using the SIFT Algorithm. Nat. Protoc. 2009, 4, 1073–1081. [Google Scholar] [CrossRef]
  18. Adzhubei, I.; Jordan, D.M.; Sunyaev, S.R. Predicting Functional Effect of Human Missense Mutations Using PolyPhen-2. Curr. Protoc. Hum. Genet. 2013, 76, 7.20.1–7.20.41. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  19. Schwarz, J.M.; Rödelsperger, C.; Schuelke, M.; Seelow, D. MutationTaster Evaluates Disease-Causing Potential of Sequence Alterations. Nat. Methods 2010, 7, 575–576. [Google Scholar] [CrossRef]
  20. Povysil, G.; Tzika, A.; Vogt, J.; Haunschmid, V.; Messiaen, L.; Zschocke, J.; Klambauer, G.; Hochreiter, S.; Wimmer, K. Panelcn.MOPS: Copy-Number Detection in Targeted NGS Panel Data for Clinical Diagnostics. Hum. Mutat. 2017, 38, 889–897. [Google Scholar] [CrossRef] [Green Version]
  21. Zhang, W.; Cui, H.; Wong, L.-J.C. Comprehensive One-Step Molecular Analyses of Mitochondrial Genome by Massively Parallel Sequencing. Clin. Chem. 2012, 58, 1322–1331. [Google Scholar] [CrossRef] [Green Version]
  22. Nogueira, C.; Silva, L.; Pereira, C.; Vieira, L.; Leão Teles, E.; Rodrigues, E.; Campos, T.; Janeiro, P.; Gaspar, A.; Dupont, J.; et al. Targeted next Generation Sequencing Identifies Novel Pathogenic Variants and Provides Molecular Diagnoses in a Cohort of Pediatric and Adult Patients with Unexplained Mitochondrial Dysfunction. Mitochondrion 2019, 47, 309–317. [Google Scholar] [CrossRef]
  23. De Vries, D.D.; Van Engelen, B.G.M.; Gabreëls, F.J.M.; Ruitenbeek, W.; Van Oost, B.A. A Second Missense Mutation in the Mitochondrial ATPase 6 Gene in Leigh’s Syndrome: MtDNA Mutation in Leigh’s Syndrome. Ann. Neurol. 1993, 34, 410–412. [Google Scholar] [CrossRef]
  24. Moslemi, A.-R.; Darin, N.; Tulinius, M.; Oldfors, A.; Holme, E. Two New Mutations in the MTATP6 Gene Associated with Leigh Syndrome. Neuropediatrics 2005, 36, 314–318. [Google Scholar] [CrossRef]
  25. Thyagarajan, D.; Shanske, S.; Vazquez-Memije, M.; Devivo, D.; Dimauro, S. A Novel Mitochondrial ATPase 6 Point Mutation in Familial Bilateral Striatal Necrosis. Ann. Neurol. 1995, 38, 468–472. [Google Scholar] [CrossRef]
  26. Poulton, J.; Turnbull, D.M.; Mehta, A.B.; Wilson, J.; Gardiner, R.M. Restriction Enzyme Analysis of the Mitochondrial Genome in Mitochondrial Myopathy. J. Med. Genet. 1988, 25, 600–605. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  27. Kirby, D.M.; Salemi, R.; Sugiana, C.; Ohtake, A.; Parry, L.; Bell, K.M.; Kirk, E.P.; Boneh, A.; Taylor, R.W.; Dahl, H.-H.M.; et al. NDUFS6 Mutations Are a Novel Cause of Lethal Neonatal Mitochondrial Complex I Deficiency. J. Clin. Investig. 2004, 114, 837–845. [Google Scholar] [CrossRef]
  28. Valente, L.; Piga, D.; Lamantea, E.; Carrara, F.; Uziel, G.; Cudia, P.; Zani, A.; Farina, L.; Morandi, L.; Mora, M.; et al. Identification of Novel Mutations in Five Patients with Mitochondrial Encephalomyopathy. Biochim. Biophys. Acta BBA-Bioenerg. 2009, 1787, 491–501. [Google Scholar] [CrossRef] [Green Version]
  29. Chol, M. The Mitochondrial DNA G13513A MELAS Mutation in the NADH Dehydrogenase 5 Gene Is a Frequent Cause of Leigh-like Syndrome with Isolated Complex I Deficiency. J. Med. Genet. 2003, 40, 188–191. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  30. Pereira, C.; Souza, C.F.D.; Vedolin, L.; Vairo, F.; Lorea, C.; Sobreira, C.; Nogueira, C.; Vilarinho, L. Leigh Syndrome Due to MtDNA Pathogenic Variants. J. Inborn Errors Metab. Screen. 2019, 7, e2018000320. [Google Scholar] [CrossRef] [Green Version]
  31. Vilarinho, L.; Maia, C.; Coelho, T.; Coutinho, P.; Santorelli, F.M. Heterogeneous Presentation in Leigh Syndrome. J. Inherit. Metab. Dis. 1997, 20, 704–705. [Google Scholar] [CrossRef] [PubMed]
  32. Richards, S.; Aziz, N.; Bale, S.; Bick, D.; Das, S.; Gastier-Foster, J.; Grody, W.W.; Hegde, M.; Lyon, E.; Spector, E.; et al. Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 2015, 17, 405–424. [Google Scholar] [CrossRef] [Green Version]
  33. Debs, R.; Depienne, C.; Rastetter, A.; Bellanger, A.; Degos, B.; Galanaud, D.; Keren, B.; Lyon-Caen, O.; Brice, A.; Sedel, F. Biotin-Responsive Basal Ganglia Disease in Ethnic Europeans with Novel SLC19A3 Mutations. Arch. Neurol. 2010, 67, 126–130. [Google Scholar] [CrossRef]
  34. Peters, H.; Buck, N.; Wanders, R.; Ruiter, J.; Waterham, H.; Koster, J.; Yaplito-Lee, J.; Ferdinandusse, S.; Pitt, J. ECHS1 Mutations in Leigh Disease: A New Inborn Error of Metabolism Affecting Valine Metabolism. Brain 2014, 137, 2903–2908. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  35. Peters, H.; Ferdinandusse, S.; Ruiter, J.P.; Wanders, R.J.A.; Boneh, A.; Pitt, J. Metabolite Studies in HIBCH and ECHS1 Defects: Implications for Screening. Mol. Genet. Metab. 2015, 115, 168–173. [Google Scholar] [CrossRef]
  36. Bénit, P.; Beugnot, R.; Chretien, D.; Giurgea, I.; De Lonlay-Debeney, P.; Issartel, J.-P.; Corral-Debrinski, M.; Kerscher, S.; Rustin, P.; Rötig, A.; et al. Mutant NDUFV2 Subunit of Mitochondrial Complex I Causes Early Onset Hypertrophic Cardiomyopathy and Encephalopathy: NDUFV2 and cardiomyopathy/encephalopathy. Hum. Mutat. 2003, 21, 582–586. [Google Scholar] [CrossRef]
  37. Tiranti, V.; Hoertnagel, K.; Carrozzo, R.; Galimberti, C.; Munaro, M.; Granatiero, M.; Zelante, L.; Gasparini, P.; Marzella, R.; Rocchi, M.; et al. Mutations of SURF-1 in Leigh Disease Associated with Cytochrome c Oxidase Deficiency. Am. J. Hum. Genet. 1998, 63, 1609–1621. [Google Scholar] [CrossRef] [Green Version]
  38. Wojcik, M.H.; Schwartz, T.S.; Thiele, K.E.; Paterson, H.; Stadelmaier, R.; Mullen, T.E.; VanNoy, G.E.; Genetti, C.A.; Madden, J.A.; Gubbels, C.S.; et al. Infant Mortality: The Contribution of Genetic Disorders. J. Perinatol. 2019, 39, 1611–1619. [Google Scholar] [CrossRef]
  39. Ganetzky, R.D.; Stendel, C.; McCormick, E.M.; Zolkipli-Cunningham, Z.; Goldstein, A.C.; Klopstock, T.; Falk, M.J. MT-ATP6 Mitochondrial Disease Variants: Phenotypic and Biochemical Features Analysis in 218 Published Cases and Cohort of 14 New Cases. Hum. Mutat. 2019, 40, 499–515. [Google Scholar] [CrossRef] [PubMed]
  40. Rojo, A.; Campos, Y.; Sánchez, J.M.; Bonaventura, I.; Aguilar, M.; García, A.; González, L.; Rey, M.J.; Arenas, J.; Olivé, M.; et al. NARP-MILS Syndrome Caused by 8993 T > G Mitochondrial DNA Mutation: A Clinical, Genetic and Neuropathological Study. Acta Neuropathol. 2006, 111, 610–616. [Google Scholar] [CrossRef]
  41. Craig, K.; Elliott, H.R.; Keers, S.M.; Lambert, C.; Pyle, A.; Graves, T.D.; Woodward, C.; Sweeney, M.G.; Davis, M.B.; Hanna, M.G.; et al. Episodic Ataxia and Hemiplegia Caused by the 8993T→C Mitochondrial DNA Mutation. J. Med. Genet. 2007, 44, 797–799. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  42. Balasubramaniam, S.; Lewis, B.; Mock, D.M.; Said, H.M.; Tarailo-Graovac, M.; Mattman, A.; Van Karnebeek, C.D.; Thorburn, D.R.; Rodenburg, R.J.; Christodoulou, J. Leigh-Like Syndrome Due to Homoplasmic m.8993T>G Variant with Hypocitrullinemia and Unusual Biochemical Features Suggestive of Multiple Carboxylase Deficiency (MCD). In JIMD Reports; Morava, E., Baumgartner, M., Patterson, M., Rahman, S., Zschocke, J., Peters, V., Eds.; Springer: Berlin/Heidelberg, Germany, 2016; Volume 33, pp. 99–107. [Google Scholar] [CrossRef] [Green Version]
  43. Debray, F.-G.; Lambert, M.; Allard, P.; Mitchell, G.A. Low Citrulline in Leigh Disease: Still a Biomarker of Maternally Inherited Leigh Syndrome. J. Child Neurol. 2010, 25, 1000–1002. [Google Scholar] [CrossRef] [PubMed]
  44. Peretz, R.H.; Ah Mew, N.; Vernon, H.J.; Ganetzky, R.D. Prospective Diagnosis of MT-ATP6-Related Mitochondrial Disease by Newborn Screening. Mol. Genet. Metab. 2021, 134, 37–42. [Google Scholar] [CrossRef]
  45. Tise, C.G.; Verscaj, C.P.; Mendelsohn, B.A.; Woods, J.; Lee, C.U.; Enns, G.M.; Stander, Z.; Hall, P.L.; Cowan, T.M.; Cusmano-Ozog, K.P. MT-ATP6 Mitochondrial Disease Identified by Newborn Screening Reveals a Distinct Biochemical Phenotype. Am. J. Med. Genet. A 2023, 191, 1492–1501. [Google Scholar] [CrossRef]
  46. Larson, A.A.; Balasubramaniam, S.; Christodoulou, J.; Burrage, L.C.; Marom, R.; Graham, B.H.; Diaz, G.A.; Glamuzina, E.; Hauser, N.; Heese, B.; et al. Biochemical Signatures Mimicking Multiple Carboxylase Deficiency in Children with Mutations in MT-ATP6. Mitochondrion 2019, 44, 58–64. [Google Scholar] [CrossRef] [PubMed]
  47. Childs, A.-M.; Hutchin, T.; Pysden, K.; Highet, L.; Bamford, J.; Livingston, J.; Crow, Y. Variable Phenotype Including Leigh Syndrome with a 9185T>C Mutation in the MTATP6 Gene. Neuropediatrics 2007, 38, 313–316. [Google Scholar] [CrossRef]
  48. Pfeffer, G.; Blakely, E.L.; Alston, C.L.; Hassani, A.; Boggild, M.; Horvath, R.; Samuels, D.C.; Taylor, R.W.; Chinnery, P.F. Adult-Onset Spinocerebellar Ataxia Syndromes Due to MTATP6 Mutations. J. Neurol. Neurosurg. Psychiatry 2012, 83, 883–886. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  49. Takada, R.; Tozawa, T.; Kondo, H.; Kizaki, Z.; Kishita, Y.; Okazaki, Y.; Murayama, K.; Ohtake, A.; Chiyonobu, T. Early Infantile-Onset Leigh Syndrome Complicated with Infantile Spasms Associated with the m.9185 T > C Variant in the MT-ATP6 Gene: Expanding the Clinical Spectrum. Brain Dev. 2020, 42, 69–72. [Google Scholar] [CrossRef] [Green Version]
  50. Pan, X.; Wang, L.; Fei, G.; Dong, J.; Zhong, C.; Lu, J.; Jin, L. Acute Respiratory Failure Is the Initial Manifestation in the Adult-Onset A3243G TRNALeu MtDNA Mutation: A Case Report and the Literature Review. Front. Neurol. 2019, 10, 780. [Google Scholar] [CrossRef] [Green Version]
  51. Mahale, R.R.; Gautham, J.; Mailankody, P.; Padmanabha, H.; Mathuranath, P.S. Isolated Mitochondrial Myopathy Due to m.3243A > G Mutation in MT-TL1 Gene. Acta Neurol. Belg. 2022, 122, 1115–1116. [Google Scholar] [CrossRef]
  52. Esterhuizen, K.; Lindeque, J.Z.; Mason, S.; Van Der Westhuizen, F.H.; Rodenburg, R.J.; De Laat, P.; Smeitink, J.A.M.; Janssen, M.C.H.; Louw, R. One Mutation, Three Phenotypes: Novel Metabolic Insights on MELAS, MIDD and Myopathy Caused by the m.3243A > G Mutation. Metabolomics 2021, 17, 10. [Google Scholar] [CrossRef] [PubMed]
  53. Chinnery, P.F.; Taylor, D.J.; Brown, D.T.; Manners, D.; Styles, P.; Lodi, R. Very Low Levels of the MtDNA A3243G Mutation Associated with Mitochondrial Dysfunction in Vivo. Ann. Neurol. 2000, 47, 381–384. [Google Scholar] [CrossRef]
  54. Leshinsky-Silver, E.; Lev, D.; Tzofi-Berman, Z.; Cohen, S.; Saada, A.; Yanoov-Sharav, M.; Gilad, E.; Lerman-Sagie, T. Fulminant Neurological Deterioration in a Neonate with Leigh Syndrome Due to a Maternally Transmitted Missense Mutation in the Mitochondrial ND3 Gene. Biochem. Biophys. Res. Commun. 2005, 334, 582–587. [Google Scholar] [CrossRef]
  55. Malfatti, E.; Bugiani, M.; Invernizzi, F.; De Souza, C.F.-M.; Farina, L.; Carrara, F.; Lamantea, E.; Antozzi, C.; Confalonieri, P.; Sanseverino, M.T.; et al. Novel Mutations of ND Genes in Complex I Deficiency Associated with Mitochondrial Encephalopathy. Brain 2007, 130, 1894–1904. [Google Scholar] [CrossRef]
  56. Newstead, S.M.; Scorza, C.A.; Fiorini, A.C.; Scorza, F.A.; Finsterer, J. Mitochondrial Small Fiber Neuropathy as a Novel Phenotypic Trait of Leigh-like Syndrome Due to the Variant m.10191T>C in MT-ND3. Clin. Sao Paulo Braz. 2023, 78, 100206. [Google Scholar] [CrossRef] [PubMed]
  57. Swalwell, H.; Kirby, D.M.; Blakely, E.L.; Mitchell, A.; Salemi, R.; Sugiana, C.; Compton, A.G.; Tucker, E.J.; Ke, B.-X.; Lamont, P.J.; et al. Respiratory Chain Complex I Deficiency Caused by Mitochondrial DNA Mutations. Eur. J. Hum. Genet. 2011, 19, 769–775. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  58. Newstead, S.M.; Finsterer, J. Leigh-Like Syndrome with a Novel, Complex Phenotype Due to m.10191T>C in Mt-ND3. Cureus 2022, 14, e28986. [Google Scholar] [CrossRef]
  59. Lax, N.Z.; Pienaar, I.S.; Reeve, A.K.; Hepplewhite, P.D.; Jaros, E.; Taylor, R.W.; Kalaria, R.N.; Turnbull, D.M. Microangiopathy in the Cerebellum of Patients with Mitochondrial DNA Disease. Brain 2012, 135, 1736–1750. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  60. Ogawa, E.; Shimura, M.; Fushimi, T.; Tajika, M.; Ichimoto, K.; Matsunaga, A.; Tsuruoka, T.; Ishige, M.; Fuchigami, T.; Yamazaki, T.; et al. Clinical Validity of Biochemical and Molecular Analysis in Diagnosing Leigh Syndrome: A Study of 106 Japanese Patients. J. Inherit. Metab. Dis. 2017, 40, 685–693. [Google Scholar] [CrossRef] [Green Version]
  61. Ardissone, A.; Ferrera, G.; Lamperti, C.; Tiranti, V.; Ghezzi, D.; Moroni, I.; Lamantea, E. Phenotyping mitochondrial DNA-related Diseases in Childhood: A Cohort Study of 150 Patients. Eur. J. Neurol. 2023, 30, 2079–2091. [Google Scholar] [CrossRef] [PubMed]
  62. Ruiter, E.M.; Siers, M.H.; Van Den Elzen, C.; Van Engelen, B.G.; Smeitink, J.A.M.; Rodenburg, R.J.; Hol, F.A. The Mitochondrial 13513G>A Mutation Is Most Frequent in Leigh Syndrome Combined with Reduced Complex I Activity, Optic Atrophy and/or Wolff–Parkinson–White. Eur. J. Hum. Genet. 2007, 15, 155–161. [Google Scholar] [CrossRef] [Green Version]
  63. Goldstein, A.; Falk, M.J. Mitochondrial DNA Deletion Syndromes; University of Washington: Seattle, WA, USA, 2019. [Google Scholar]
  64. Reynolds, E.; Byrne, M.; Ganetzky, R.; Parikh, S. Pediatric Single Large-Scale MtDNA Deletion Syndromes: The Power of Patient Reported Outcomes. Mol. Genet. Metab. 2021, 134, 301–308. [Google Scholar] [CrossRef]
  65. McShane, M.A.; Hardingt, A.E. Pearson Syndrome and Mitochondrial Encephalomyopathy in a Patient with a Deletion of MtDNA. Am. J. Hum. Genet. 1991, 48, 39. [Google Scholar] [PubMed]
  66. Rötig, A.; Bourgeron, T.; Chretien, D.; Rustin, P.; Munnich, A. Spectrum of Mitochondrial DNA Rearrangements in the Pearson Marrow-Pancreas Syndrome. Hum. Mol. Genet. 1995, 4, 1327–1330. [Google Scholar] [CrossRef]
  67. Incecik, F.; Herguner, O.; Besen, S.; Bozdoğan, S.; Mungan, N. Late-Onset Leigh Syndrome Due to NDUFV1 Mutation in a 10-Year-Old Boy Initially Presenting with Ataxia. J. Pediatr. Neurosci. 2018, 13, 205. [Google Scholar] [CrossRef]
  68. Fassone, E.; Rahman, S. Complex I Deficiency: Clinical Features, Biochemistry and Molecular Genetics. J. Med. Genet. 2012, 49, 578–590. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  69. Men, L.; Feng, J.; Huang, W.; Xu, M.; Zhao, X.; Sun, R.; Xu, J.; Cao, L. Lip Cyanosis as the First Symptom of Leigh Syndrome Associated with Mitochondrial Complex I Deficiency Due to a Compound Heterozygous NDUFS1 Mutation: A Case Report. Med. (Baltim.) 2022, 101, e30303. [Google Scholar] [CrossRef]
  70. Koene, S.; Rodenburg, R.J.; Van Der Knaap, M.S.; Willemsen, M.A.A.P.; Sperl, W.; Laugel, V.; Ostergaard, E.; Tarnopolsky, M.; Martin, M.A.; Nesbitt, V.; et al. Natural Disease Course and Genotype-Phenotype Correlations in Complex I Deficiency Caused by Nuclear Gene Defects: What We Learned from 130 Cases. J. Inherit. Metab. Dis. 2012, 35, 737–747. [Google Scholar] [CrossRef] [Green Version]
  71. Loeffen, J.L.C.M.; Smeitink, J.A.M.; Trijbels, J.M.F.; Janssen, A.J.M.; Triepels, R.H.; Sengers, R.C.A.; Van Den Heuvel, L.P. Isolated Complex I Deficiency in Children: Clinical, Biochemical and Genetic Aspects. Hum. Mutat. 2000, 15, 123–134. [Google Scholar] [CrossRef]
  72. Werner, K.G.E.; Morel, C.F.; Kirton, A.; Benseler, S.M.; Shoffner, J.M.; Addis, J.B.L.; Robinson, B.H.; Burrowes, D.M.; Blaser, S.I.; Epstein, L.G.; et al. Rolandic Mitochondrial Encephalomyelopathy and MT-ND3 Mutations. Pediatr. Neurol. 2009, 41, 27–33. [Google Scholar] [CrossRef]
  73. Pagniez-Mammeri, H.; Lombes, A.; Brivet, M.; Ogier-de Baulny, H.; Landrieu, P.; Legrand, A.; Slama, A. Rapid Screening for Nuclear Genes Mutations in Isolated Respiratory Chain Complex I Defects. Mol. Genet. Metab. 2009, 96, 196–200. [Google Scholar] [CrossRef]
  74. Cameron, J.M.; MacKay, N.; Feigenbaum, A.; Tarnopolsky, M.; Blaser, S.; Robinson, B.H.; Schulze, A. Exome Sequencing Identifies Complex I NDUFV2 Mutations as a Novel Cause of Leigh Syndrome. Eur. J. Paediatr. Neurol. 2015, 19, 525–532. [Google Scholar] [CrossRef]
  75. Liu, Z.; Zhang, L.; Ren, C.; Xu, M.; Li, S.; Ban, R.; Wu, Y.; Chen, L.; Sun, S.; Elstner, M.; et al. Whole Genome and Exome Sequencing Identify NDUFV2 Mutations as a New Cause of Progressive Cavitating Leukoencephalopathy. J. Med. Genet. 2022, 59, 351–357. [Google Scholar] [CrossRef]
  76. Shoubridge, E.A. Cytochrome c Oxidase Deficiency. Am. J. Med. Genet. 2001, 106, 46–52. [Google Scholar] [CrossRef]
  77. Oláhová, M.; Hardy, S.A.; Hall, J.; Yarham, J.W.; Haack, T.B.; Wilson, W.C.; Alston, C.L.; He, L.; Aznauryan, E.; Brown, R.M.; et al. LRPPRC Mutations Cause Early-Onset Multisystem Mitochondrial Disease Outside of the French-Canadian Population. Brain 2015, 138, 3503–3519. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  78. Baertling, F.; Mayatepek, E.; Distelmaier, F. Hypertrichosis in Presymptomatic Mitochondrial Disease. J. Inherit. Metab. Dis. 2013, 36, 1081–1082. [Google Scholar] [CrossRef]
  79. Wedatilake, Y.; Brown, R.M.; McFarland, R.; Yaplito-Lee, J.; Morris, A.A.M.; Champion, M.; Jardine, P.E.; Clarke, A.; Thorburn, D.R.; Taylor, R.W.; et al. SURF1 Deficiency: A Multi-Centre Natural History Study. Orphanet J. Rare Dis. 2013, 8, 96. [Google Scholar] [CrossRef] [Green Version]
  80. Mahdieh, N.; Soveizi, M.; Tavasoli, A.R.; Rabbani, A.; Ashrafi, M.R.; Kohlschütter, A.; Rabbani, B. Genetic Testing of Leukodystrophies Unraveling Extensive Heterogeneity in a Large Cohort and Report of Five Common Diseases and 38 Novel Variants. Sci. Rep. 2021, 11, 3231. [Google Scholar] [CrossRef]
  81. Debray, F.-G.; Morin, C.; Janvier, A.; Villeneuve, J.; Maranda, B.; Laframboise, R.; Lacroix, J.; Decarie, J.-C.; Robitaille, Y.; Lambert, M.; et al. LRPPRC Mutations Cause a Phenotypically Distinct Form of Leigh Syndrome with Cytochrome c Oxidase Deficiency. J. Med. Genet. 2011, 48, 183–189. [Google Scholar] [CrossRef]
  82. Distelmaier, F.; Huppke, P.; Pieperhoff, P.; Amunts, K.; Schaper, J.; Morava, E.; Mayatepek, E.; Kohlhase, J.; Karenfort, M. Biotin-Responsive Basal Ganglia Disease: A Treatable Differential Diagnosis of Leigh Syndrome. In JIMD Reports-Case and Research Reports; Zschocke, J., Gibson, K.M., Brown, G., Morava, E., Peters, V., Eds.; JIMD Reports; Springer: Berlin/Heidelberg, Germany, 2013; Volume 13, pp. 53–57. [Google Scholar] [CrossRef] [Green Version]
  83. Ortigoza-Escobar, J.D.; Molero-Luis, M.; Arias, A.; Oyarzabal, A.; Darín, N.; Serrano, M.; Garcia-Cazorla, A.; Tondo, M.; Hernández, M.; Garcia-Villoria, J.; et al. Free-Thiamine Is a Potential Biomarker of Thiamine Transporter-2 Deficiency: A Treatable Cause of Leigh Syndrome. Brain 2016, 139, 31–38. [Google Scholar] [CrossRef]
  84. Wang, J.; Wang, J.; Han, X.; Liu, Z.; Ma, Y.; Chen, G.; Zhang, H.; Sun, D.; Xu, R.; Liu, Y.; et al. Report of the Largest Chinese Cohort with SLC19A3 Gene Defect and Literature Review. Front. Genet. 2021, 12, 683255. [Google Scholar] [CrossRef] [PubMed]
  85. Tabarki, B.; Al-Hashem, A.; Alfadhel, M. Biotin-Thiamine-Responsive Basal Ganglia Disease; University of Washington: Seattle, WA, USA, 2020. [Google Scholar]
  86. Olgiati, S.; Skorvanek, M.; Quadri, M.; Minneboo, M.; Graafland, J.; Breedveld, G.J.; Bonte, R.; Ozgur, Z.; Van Den Hout, M.C.G.N.; Schoonderwoerd, K.; et al. Paroxysmal Exercise-Induced Dystonia within the Phenotypic Spectrum of ECHS1 Deficiency: ECHS1 Mutations, Dystonia, and PED. Mov. Disord. 2016, 31, 1041–1048. [Google Scholar] [CrossRef] [PubMed]
  87. Ganetzky, R.D.; Bloom, K.; Ahrens-Nicklas, R.; Edmondson, A.; Deardorff, M.A.; Bennett, M.J.; Ficicioglu, C. ECHS1 Deficiency as a Cause of Severe Neonatal Lactic Acidosis. In JIMD Reports; Morava, E., Baumgartner, M., Patterson, M., Rahman, S., Zschocke, J., Peters, V., Eds.; Springer: Berlin/Heidelberg, Germany, 2016; Volume 30, pp. 33–37. [Google Scholar] [CrossRef] [Green Version]
  88. Ferdinandusse, S.; Waterham, H.R.; Heales, S.J.; Brown, G.K.; Hargreaves, I.P.; Taanman, J.-W.; Gunny, R.; Abulhoul, L.; Wanders, R.J.; Clayton, P.T.; et al. HIBCH Mutations Can Cause Leigh-like Disease with Combined Deficiency of Multiple Mitochondrial Respiratory Chain Enzymes and Pyruvate Dehydrogenase. Orphanet J. Rare Dis. 2013, 8, 188. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  89. Çakar, N.; Görükmez, O. 3-Hydroxyisobutyryl-CoA Hydrolase (HIBCH) Deficiency Cases Diagnosed by Only HIBCH Gene Analysis and Novel Pathogenic Mutation. Ann. Indian Acad. Neurol. 2021, 24, 372. [Google Scholar] [CrossRef] [PubMed]
  90. Marti-Sanchez, L.; Baide-Mairena, H.; Marcé-Grau, A.; Pons, R.; Skouma, A.; López-Laso, E.; Sigatullina, M.; Rizzo, C.; Semeraro, M.; Martinelli, D.; et al. Delineating the Neurological Phenotype in Children with Defects in the ECHS1 or HIBCH Gene. J. Inherit. Metab. Dis. 2021, 44, 401–414. [Google Scholar] [CrossRef] [PubMed]
Genes 14 01536 g001 550
Figure 1. Mitochondrial and nuclear genes with mutations in our cohort, implicated in LSS.
Figure 1. Mitochondrial and nuclear genes with mutations in our cohort, implicated in LSS.
Genes 14 01536 g001
Table
Table 1. LSS clinical and radiological features [9].
Table 1. LSS clinical and radiological features [9].
Leigh Syndrome Spectrum (LSS)
Clinical features *Metabolic decompensation (elevated lactate levels in blood and/or cerebrospinal fluid) and/or characteristic symptoms during acute illness (episodic).
Neurologic manifestations: hypotonia, spasticity, movement disorders (dystonia, chorea), cerebellar ataxia, and peripheral neuropathy.
Other systems manifestations: hypertrophic cardiomyopathy, anemia, renal tubulopathy, liver involvement, ptosis, and muscle weakness.
Radiological featuresMultiple symmetric bilateral lesions in the basal ganglia, thalamus, brain stem, dentate nuclei, and optic nerves **.
Legend: * Includes LLS features, such as: no evidence of abnormal energy metabolism, atypical neuropathology, and/or incomplete evaluation, to the classic LS criteria resulting in LSS. ** Unilateral lesions in brain stem, basal ganglia, spinal cord, cerebellum; variation in the distribution or character of lesions or with the additional presence of unusual features, such as extensive cortical destruction (neuronal loss).
Table
Table 2. Results of investigation of LSS patients’ mtDNA in this cohort.
Table 2. Results of investigation of LSS patients’ mtDNA in this cohort.
GenderAge of DiagnosisGene Mutation DataSymptoms
VariantHeteroplasmyStatus
(Mitomap) [22]		Reference
P1F7 yMT-ATP6m.8993T>G (p.Leu156Arg)Muscle: 95%PHolt, 1990 [4] Psychomotor regression, loss of contact, lethargy, generalized seizures, dystonia.
P2F2 yMT-ATP6m.8993T>G (p.Leu156Arg)Muscle: homoplasmicPHolt, 1990 [4] Hypotonia, progression to apnea after febrile illness, dystonia.
P3 F8 yMT-ATP6m.8993T>G (p.Leu156Arg)Blood: homoplasmicPHolt, 1990 [4] Intellectual impairment, spastic paraparesis, hyperlactacidemia.
P4 F9 y MT-ATP6m.8993T>G (p.Leu156Arg)Blood: 95%PHolt, 1990 [4] Mitochondrial encephalopathy.
P5M1 yMT-ATP6m.8993T>G (p.Leu156Arg)Muscle: 95%PHolt, 1990 [4] Hypotonia, myoclonic epilepsy, regression of milestones.
P6F29 yMT-ATP6m.8993T>G (p.Leu156Arg)Blood and muscle: >95%PHolt, 1990 [4] LSS
P7F16 yMT-ATP6m.8993T>G (p.Leu156Arg)Muscle: 75%PHolt, 1990 [4] LSS
P8M6 yMT-ATP6m.8993T>G (p.Leu156Arg)Muscle: 85%PHolt, 1990 [4] LSS
P9M1 yMT-ATP6m.8993T>G (p.Leu156Arg)Blood and muscle: homoplasmicPHolt, 1990 [4] LSS
P10F1 yMT-ATP6m.8993T>G (p.Leu156Arg)Muscle: 90%PHolt, 1990 [4] Neurodevelopmental delay, hypotonia, epilepsy.
P11F19 yMT-ATP6m.8993T>G (p.Leu156Arg)Muscle: 95%PHolt, 1990 [4] Deafness, peripheral neuropathy, ataxia.
P12F2 yMT-ATP6m.8993T>G (p.Leu156Arg)Muscle: 98%PHolt, 1990 [4] Failure to thrive, eosinophilic esophagitis.
P13F23 yMT-ATP6m.8993T>C (p.Leu156Pro) Muscle: >95%PDe Vries, 1993 [23]LSS
P14M8 yMT-ATP6m.8993T>C (p.Leu156Pro) Muscle: >95%PDe Vries, 1993 [23]LSS
P15F10 yMT-ATP6m.8993T>C (p.Leu156Pro) Blood and muscle: >90%PDe Vries, 1993 [23]Numbness, ataxia.
P16M8 yMT-ATP6m.8993T>C (p.Leu156Pro) Muscle: 98%PDe Vries, 1993 [23]Mitochondrial disorder.
P17F1 yMT-ATP6m.9185T>C (p.Leu220Pro) Muscle: 70%PMoslemi, 2005 [24]Neurodevelopmental delay, microcephaly and hypotonia.
P18M32 yMT-ATP7m.9185T>C (p.Leu220Pro) Blood: homoplasmicPMoslemi, 2005 [24]LSS
P19M0 m.o.MT-ATP6m.9176T>G (p.Leu217Arg) Blood: homoplasmicPThyagarajan, 1995 [25]Still asymptomatic (studied to clarify newborn screening alterations).
P20M10 yMT-TL1m.3243A>G Muscle: 73%PPoulton, 1988 [26]Epilepsy, learning disability, ataxia, hyperlactacidemia.
P21F4 yMT-ND3m.10191T>C (p.Ser45Pro) Blood: 80%, muscle: 90%PTaylor, 2001 [6]Hypotonia, neurodevelopmental delay, recurrent respiratory infections in first months of life, epilepsy.
P22M7 yMT-ND3m.10197G>A (p.Ala47Tre)Muscle: 100%PKirby, 2004 [27]Epilepsy, failure to thrive, recurrent illness, hypotonia, high serum lactate levels.
P23M11 yMT-ND5m.13094T>C (p.Val253Ala)Blood: 100%PValente, 2009 [28]Severe hypotonia.
P24F8 m.o.MT-ND5m.13513G>A (p.Asp393Asn)Blood: 70%PChol, 2003 [29]Neurodevelopmental delay, cardiomyopathy, hypotonia.
P25M7 yMT-ND5m.13513G>A (p.Asp393Asn)Blood: 58%, muscle: 88%PChol, 2003 [29]Ataxia and apnea.
P26M12 yMT-ND1m.4142G>T (p.Arg279Leu)Muscle: 80%RPereira, 2019 [30]Spastic deambulation with cerebellar signs, hyperreflexia, clonus, dysarthria, dystonia, cognitive impairment.
P27M13 yMT-CO1m.6547T>C (p.Leu215Pro)Muscle: 50%RPereira, 2019 [30]Hypotonia, hyperlactacidemia.
P28M7 yMT-ATP6 to MT-ND54977bp-del (m.8470-m.13447)Muscle: 61%PVilarinho, 1997 [31]Epilepsy, short stature, cerebellar ataxia, tremor.
Legend: LSS: Leigh syndrome spectrum; y: year; F: female, M: male P: confirmedly pathogenic; R: reported; m.o.: months old.
Table
Table 3. Results of investigation of LSS patients’ nDNA in this cohort.
Table 3. Results of investigation of LSS patients’ nDNA in this cohort.
PatientGenderAge of DiagnosisGeneMutation DataSymptoms
Allele 1ReferenceClinVarClinVar PhenotypeAllele 2ReferenceClinVarClinVar Phenotype
P29M36 yNDUFS8c.196C>T (p. Arg66*)Nogueira, 2019 [22]NDNDc.287G>A (p.Arg96 His)Nogueira, 2019 [22]NDNDShort stature, Leigh syndrome compatible neuroimaging.
P30M2 yNDUFS1c.470A>T (p.Lys157 Met)NDNDNDc.1798G>C (p.Glu600 Gln)NDNDNDAxial hypotonia, failure to thrive, neurodevelopmental delay, nystagmus.
P31F2 yNDUFV2c.120+5_ 120+8 delGTBénit, 2003 [36]PMitochondrial Complex I deficiencyc.120+5_ 120+8 delGTBénit, 2003 [36]PMitochondrial Complex I deficiencySevere eczema, epilepsy, axial hypotonia, neurodevelopmental delay, suspicion of Leigh syndrome.
P32Mprenatalc.120+5_ 120+8 delGTBénit, 2003 [36]PMitochondrial Complex I deficiencyc.120+5_ 120+8 delGTBénit, 2003 [36]PMitochondrial Complex I deficiencyPrenatal screening, P31 sibling.
P33F3 ySURF1c.19_35dup17* (p.Ala13 Cysfs*65)Tiranti, 1998 [37]PLSSc.845_846 del (p:Ser282 Cysfs*9)Tiranti, 1998 [37]P/LPLSSAtaxia, hypotonia, tremors, Tetralogy of Fallot.
P34F1 yc.19_35dup17* (p.Ala13 Cysfs*65)Tiranti, 1998 [37]PLSSc.845_846 del (p:Ser282 Cysfs*9)Tiranti, 1998 [37]P/LPLSSNeurodevelopmental delay, hypotonia, bradycardia.
P35M15 yc.19_35dup17* (p.Ala13 Cysfs*65)Tiranti, 1998 [37]PLSSc.19_35dup17* (p.Ala13 Cysfs*65)Tiranti, 1998 [37]PLSSVisual hallucinations.
P36F4 yLRPPRCc.74G>A
(p.Arg25
His)		NDVUSCongenit lactic acidosisc.74G>A
(p. Arg25
His)		NDVUSCongenit lactic acidosisEncephalopathy, brain atrophy.
P37F1ySLC19A3c.74dupT (p.Ser26 Leufs*19)Debs, 2010 [33]PBBGDc.74dupT (p.Ser26 Leufs*19)Debs, 2010 [33]PBBGDNeonatal epileptic encephalopathy responsive to biotin, thiamine, Coenzyme Q10 and riboflavin.
P38F5yc.980-14A>GDebs, 2010 [33]LPBBGDc.177G>A (p.Trp59*)Debs, 2010 [33]NDNDEpisodic ataxia responsive to biotin, thiamine, Coenzyme Q10 and riboflavin.
P39M3 m.o.HIBCHc.488G>T (p.Cys 163Phe)Wojcik, 2019 [38]LPHIBCH deficiencyc.488G>T (p.Cys 163Phe)Wojcik, 2019 [38]LPHIBCH deficiencyStop of progression of the neurodevelopment and feeding difficulties.
P40F6 yc.129dupA (p.Gly44 Argfs*20)Peters, 2015 [35]LPHIBCH deficiencyc.910C>T (p.Pro304 Ser)NDNDNDAxial hypotonia, psychomotor regression after intercurrent illness, ataxia.
Legend: ND: not described; P: pathogenic; LP: likely pathogenic; m.o.: months old.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Baldo, M.S.; Nogueira, C.; Pereira, C.; Janeiro, P.; Ferreira, S.; Lourenço, C.M.; Bandeira, A.; Martins, E.; Magalhães, M.; Rodrigues, E.; et al. Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era. Genes 2023, 14, 1536. https://doi.org/10.3390/genes14081536

AMA Style

Baldo MS, Nogueira C, Pereira C, Janeiro P, Ferreira S, Lourenço CM, Bandeira A, Martins E, Magalhães M, Rodrigues E, et al. Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era. Genes. 2023; 14(8):1536. https://doi.org/10.3390/genes14081536

Chicago/Turabian Style

Baldo, Manuela Schubert, Célia Nogueira, Cristina Pereira, Patrícia Janeiro, Sara Ferreira, Charles M. Lourenço, Anabela Bandeira, Esmeralda Martins, Marina Magalhães, Esmeralda Rodrigues, and et al. 2023. "Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era" Genes 14, no. 8: 1536. https://doi.org/10.3390/genes14081536

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop